Amgen Inc. ($AMGN) Stock Forecast: Down 6.3% Today

What is Amgen Inc.?

AMGN refers to Amgen Inc., a biotechnology company known for developing innovative medicines. The stock is listed on the NASDAQ exchange.

Why is Amgen Inc. going down?

AMGN stock is down 6.3% on Apr 17, 2025 13:38

• Amgen's stock experienced a bearish movement likely due to the lawsuit filed by Sandoz alleging illegal blocking of biosimilar competition for Enbrel, a significant revenue-generating arthritis drug.
• The legal battle and uncertainty surrounding the availability of Erelzi in the U.S. due to contested patents for Enbrel could have contributed to the negative market sentiment towards Amgen.
• Despite a slight gain in a recent trading session, the overall bearish trend today could be attributed to concerns over potential legal implications and competition affecting Amgen's market position and revenue streams.

AMGN Price Chart

AMGN Technical Analysis

AMGN News

Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug - Sandoz Group ( OTC:SDZNY ) , Amgen ( NASDAQ:AMGN )

Enbrel generated $3.3 billion in U.S. revenue in 2024 alone. Erelzi, FDA-approved in 2016, remains unavailable in the U.S. due to contested Enbrel patents. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds profits in volatile ...

https://www.benzinga.com/general/biotech/25/04/44795469/sandoz-files-lawsuit-alleging-amgen-illegally-blocked-biosimilar-competition-for-its-blockbuster-

Amgen ( AMGN ) Gains But Lags Market: What You Should Know

In the latest trading session, Amgen (AMGN) closed at $285.92, marking a +1.6% move from the previous day.

https://www.zacks.com/stock/news/2448051/amgen-amgn-gains-but-lags-market-what-you-should-know

Trending Today

Mantle ($MNT) Crypto Forecast: Up 5.5% Today

Wormhole ($W) Crypto Forecast: Up 5.1% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 5.2% Today

Hedera Hashgraph ($HBAR) Crypto Forecast: Up 5.3% Today

Polkadot ($DOT) Crypto Forecast: Up 5.2% Today

Ondo ($ONDO) Crypto Forecast: Up 6.3% Today

Gala ($GALA) Crypto Forecast: Up 5.6% Today

NEAR Protocol ($NEAR) Crypto Forecast: Up 5.1% Today

Memecoin ($MEME) Crypto Forecast: Down 6.1% Today

Sui ($SUI) Crypto Forecast: Up 12.3% Today

Amgen Inc. Price History

15.10.2024 - AMGN Stock was down 5.2%

• Concerns over the impact of Amgen's experimental weight loss injection, MariTide, on bone density appeared to have a notable effect on investor sentiment.
• Despite a surge in options trading and optimistic sentiments from well-funded investors, the safety concerns linked to MariTide outweighed the positive market sentiment.
• Comments from Jim Cramer on the stock's performance and potential advantages for competitor Eli Lilly notably contributed to the downward pressure on Amgen's shares.
• Overall, the market's response to the safety concerns surrounding MariTide eclipsed any positive developments, resulting in the decline of Amgen's stock price.

20.11.2024 - AMGN Stock was up 5.4%

• Despite a slight decrease in the most recent trading session, the overall bullish movement of Amgen's stock indicates strong investor confidence in the company.
• The -0.21% shift may be attributed to minor profit-taking or market fluctuations rather than any significant negative news impacting the company.
• Investors continue to show interest in Amgen due to its robust pipeline of biopharmaceutical products and potential for future growth in the healthcare industry.
• The positive sentiment towards Amgen aligns with the broader market optimism towards biotech companies, driving the stock's bullish movement.

17.03.2025 - AMGN Stock was down 6.3%

• Amgen's stock experienced a bearish movement likely due to the lawsuit filed by Sandoz alleging illegal blocking of biosimilar competition for Enbrel, a significant revenue-generating arthritis drug.
• The legal battle and uncertainty surrounding the availability of Erelzi in the U.S. due to contested patents for Enbrel could have contributed to the negative market sentiment towards Amgen.
• Despite a slight gain in a recent trading session, the overall bearish trend today could be attributed to concerns over potential legal implications and competition affecting Amgen's market position and revenue streams.

05.01.2025 - AMGN Stock was up 5.4%

• The strong bullish movement of Amgen (AMGN) today is attributed to an impressive Q4 earnings report that surpassed expectations in both earnings and sales, indicating the company's strong financial position and growth potential.
• Despite the FDA's decision to place a clinical hold on Amgen's obesity candidate, AMG 513, which initially raised concerns among investors, the overall positive earnings results overshadowed this development.
• The high bullish sentiment among investors, evident from options trading data, further boosted the stock's upward trend, reflecting a positive outlook on Amgen's future.
• Despite the regulatory setback with AMG 513, Amgen's robust performance in Q4 and the optimistic market sentiment suggest that the company is well-positioned for continued growth within the biotech sector.

05.01.2025 - AMGN Stock was up 6.6%

• During Q4, Amgen surpassed revenue and EPS expectations, impressing investors and boosting confidence in the company's growth trajectory.
• While facing a regulatory setback with the FDA's clinical hold on AMG 513 for obesity, Amgen's robust earnings performance outweighed concerns in the market.
• Favorable sentiment from influential investors and optimistic projections from analysts have contributed to Amgen's upward momentum.
• Despite regulatory hurdles, Amgen's financial strength and positive market outlook likely fueled today's significant bullish movement in the stock.

26.10.2024 - AMGN Stock was down 11.9%

• The release of data from the Phase 2 study of MariTide showing weight loss of up to 20% in obese patients might have raised concerns about the drug's market potential, leading to a bearish sentiment.
• Despite the bullish options activity on Amgen, the overall market reaction to the obesity drug data seems to have overshadowed this positive sentiment.
• The bearish movement could also be influenced by investor uncertainty surrounding the competitive profile of other companies in the biopharmaceutical sector, as seen with Silence Therapeutics' stock decline despite positive study results.

05.01.2025 - AMGN Stock was up 5.1%

• Amgen (AMGN) experienced a strong bullish movement.
• The positive sentiment may stem from expectations of surpassing Q4 earnings estimates.
• Investors are optimistic about Amgen's performance for the quarter ending December 2024, contributing to the bullish trend.
• The market movement indicates faith in Amgen's potential to deliver robust financial outcomes, sparking investor enthusiasm for the stock.

13.10.2024 - AMGN Stock was down 5.0%

• Amgen's stock saw a decrease of over 7% due to findings of bone density loss in early trials of its experimental obesity drug MariTide. Investors are worried about the drug's potential risks and its impact on the company's future revenue.
• There are speculations that the recent news could advantage competitor Eli Lilly And Co (NYSE: LLY) as investors may turn their attention towards companies with more promising drug pipelines.
• Contrarily, Amgen and AstraZeneca Plc (NASDAQ: AZN) unveiled positive data from the Phase 3 WAYPOINT trial of Tezspire for patients with chronic rhinosinusitis with nasal polyps, representing a potential success in other areas of the company's drug portfolio.

25.08.2024 - AMGN Stock was down 5.2%

• Positive Phase 3 trial results of rocatinlimab in atopic dermatitis by Amgen were overshadowed by concerns from analysts regarding market competition, impacting investor sentiment negatively.
• A federal judge's decision to reject Regeneron Pharmaceuticals' attempt to block the sale of Amgen's Eylea biosimilar potentially hints at future competition for Amgen, contributing to the bearish movement.
• Investors with significant funds showed confidence in Amgen's long-term potential through a bullish approach on the company's options, despite the day's market decline.
• The convergence of encouraging trial findings, competitive apprehensions, and legal outcomes likely triggered the bearish trend observed in Amgen's stock today.

09.03.2025 - AMGN Stock was down 5.7%

• The approval of Amgen's Uplizna for new rare autoimmune disease indications by the FDA was positive news for the company.
• Despite the positive developments with Uplizna, the stock saw a bearish trend, possibly due to profit-taking after recent spikes in the past year.
• The market's overall volatility and uncertainty may have contributed to the stock's decline despite the positive news.
• Investors might be cautious about the company's future performance, leading to a sell-off despite the overall market taking a dip.

12.10.2024 - AMGN Stock was down 5.6%

• The bearish movement in Amgen's stock today could be attributed to the positive late-stage study results of AstraZeneca and Amgen's asthma drug, Tezspire, which may have underwhelmed investors' expectations for Amgen's own pipeline.
• The strong performance of Tezspire in the Phase 3 trial for chronic rhinosinusitis with nasal polyps might have raised concerns among investors about potential competition for Amgen's existing or future respiratory disease treatments.
• Investors may be reacting to the news by selling off Amgen's stock in the short term, anticipating potential challenges or shifts in market dynamics within the respiratory disease treatment space.

04.03.2025 - AMGN Stock was down 5.0%

• The FDA approval of Uplizna as the first drug for a chronic immune-mediated fibroinflammatory disorder should have been a positive catalyst for Amgen, but the bearish movement suggests otherwise.
• Despite positive clinical data and market resilience, the stock experienced a significant plunge, possibly due to profit-taking or broader market uncertainties.
• The bearish sentiment from deep-pocketed investors, as indicated by options trading, might have contributed to the downward pressure on Amgen's stock price.
• The mixed signals from the market, including a recent rise amidst a general market dip and a slight decrease in P/E ratio, could have added to the overall confusion and led to the bearish movement in AMGN today.